Omada Health Resource Center
Real-world data analysis shows Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data
Read Article
Omada Health GLP-1 Care Track
Learn MoreIs keeping weight off after GLP-1s a concern for your members? Omada’s 16-week analysis reveals how tailored tools and support can help lead to successful weight maintenance.
Read Resource
Discover early outcomes and insights on health behavior and weight loss with Omada's Enhanced GLP-1 Care Track, specifically designed for individuals on GLP-1s seeking supportive programs.
Read Resource
The collaboration between Stanford Health Care and Omada demonstrates the value of engaging with providers and health systems to realize the value of virtual care.
Read Resource
Survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals; respondents want to lose an average of 22% more weight.
Read Article
Omada Insights Lab surveyed and interviewed Omada members with a history of GLP-1 use to learn more about their unique needs and experiences.
Read Resource
Cardiovascular disease (CVD) remains the leading cause of death among women, yet it is often misdiagnosed and/or undertreated. Join the discussion on the need for more focus on women's heart health.
Watch Video
New consumer data indicates that sustaining weight loss and overall well-being requires intervention beyond the GLP-1
Read Resource
Return on Health Framework for Realizing the Value of Virtual Care
Read Resource
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
As the healthcare industry innovates to maximize the GLP-1 experience for patients, there appears to be an important factor that’s arguably under-discussed: loneliness.
Read Article
With its checkered past and at times questioned clinical merits, BMI’s ubiquity in modern healthcare should be carefully considered.
Read Resource
Most people know that GLP-1 care can impact muscle mass, but it's important to consider the entire MSK system. Find out 3 reasons why with Omada Health.
Read Article
This insightful webinar delves into the expanding role of GLP-1 medications in treating a wide range of chronic conditions beyond diabetes and obesity.
Watch Video
New board members provide deep clinical and commercial experience.
Read Article
Omada drills into emerging details of the GLP-1 experience, including compounded GLP-1s, how to manage the drug’s impact on body composition, & ways to assess the value of virtual companion programs.
Read Article
Omada Health GLP-1 Care Track
Learn MoreQ&A with Terry Miller, VP of Machine Learning, AI and Data Science Strategy
Read Article
Economic Savings Model for Omada’s Cardiometabolic Programs
Read Article
Company pledges to keep humans at the center of care.
Read Article
How Data Science and AI learnings surprised us, taught us, and propelled us forward.
Read Article
Loading More...
